Cognitive Effects Associated With Hippocampal Neurogenesis Induced by Electroconvulsive Therapy in the Treatment of Depression

Centre Hospitalier St Anne1 site in 1 country87 target enrollmentJune 6, 2018

ConditionsMajor Depressive Disorder (MDD)Bipolar Disorder Depression

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Major Depressive Disorder (MDD)
Sponsor: Centre Hospitalier St Anne
Enrollment: 87
Locations: 1
Primary Endpoint: Correlation between increased hippocampal volume and post-ECT retrograde amnesia
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Electroconvulsive therapy (ECT) is the treatment of choice for drug-resistant depression (30% of patients), or when there is a short-term risk to the patient's life. Despite its robust efficacy and rapid onset of action, its use is limited both by the limited range of treatment available and by the cognitive effects sometimes induced. The present study focuses on the links between the efficacy of ECT, its cognitive effects and the formation of new neurons in the hippocampus (hippocampal neurogenesis) associated with this treatment.

Registry

clinicaltrials.gov

Start Date

June 6, 2018

End Date

May 14, 2024

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Centre Hospitalier St Anne

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Study population: depressed subjects treated with ECT
•Male or female over 18 years of age
•Hospitalised at the Centre Hospitalier Sainte-Anne
•Suffering from a unipolar or bipolar major depressive episode, according to DSM5 criteria
•Indication for ECT treatment
•Patient has given informed written consent
•Beneficiary of a social security scheme
•Control population: depressed subjects treated without ECT
•Male or female over 18 years of age
•Hospitalised at the Centre Hospitalier Sainte-Anne

Exclusion Criteria

•Study population: depressed subjects with ECT
•Psychiatric comorbidity: schizophrenia, pervasive developmental disorder, dependence on a substance other than tobacco
•Neurological comorbidity: Parkinson's disease, dementia
•ECT treatment in the 6 months prior to inclusion
•Compulsory care
•Protected adults, persons under court protection measures
•Persons deprived of liberty by judicial or administrative decision;
•Refusal of consent to ECT treatment
•Contraindications to ECT (HTIC, recent history of stroke, severe uncontrolled arterial hypertension, contraindication to anaesthesia)
•Contraindications to MRI (patients with metal prostheses, claustrophobia)